The effects of cannabinoids on the brain

Progress in Neurobiology

Volumn 58, Issue 4, 1999, Pages 315-348

  Ameri, Angela ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; ANANDAMIDE; CANNABINOID RECEPTOR; DRONABINOL;

AMINO ACID SEQUENCE; ANTICONVULSANT ACTIVITY; ANTINOCICEPTION; BRAIN METABOLISM; CANNABIS ADDICTION; CEREBELLUM; COGNITION; CORPUS STRIATUM; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; EUPHORIA; FACILITATION; HIPPOCAMPUS; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROTOXICITY; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN CHEMISTRY; CANNABINOIDS; HUMANS;

EID: 0032926695     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(98)00087-2     Document Type: Review

References (224)

1. Abood M.E., Martin B.R. Neurobiology of marijuana abuse. Trends Pharmacol. Sci. 13:1992;201-206.
2. Axelrod J., Felder C.C. Cannabinoid receptors and their endogenous agonist, anandamide. Neurochem. Res. 23:1998;575-581.
3. Behbehani M.M. Functional characteristics of the midbrain periaqueductal gray. Prog. Neurobiol. 46:1995;575-605.
4. Belayev L., Busto R., Zhao W., Ginsberg M.D. HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke. 26:1995;2313-2319.
5. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
6. Berrendero F., Garcia-Gil L., Hernandez M.L., Romero J., Cebeira M., de Miguel R., Ramos J.A., Fernandez-Ruiz J.J. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development. 125:1998;3179-3188.
7. Bidaut-Russell M., Howlett A.C. Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J. Neurochem. 57:1991;1769-1773.
8. Bidaut-Russell M., Devane W.A., Howlett A.C. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neurochem. 55:1990;21-26.
9. Bisogno, T., Sepe, N., Melck, D., De Petrocellis, L. and Di Marzo, V. (1998) Biosynthesis, of 2-arachidonoyl-glycerol, a novel cannabimimetic eicosanoid, in mouse neuroblastoma cells. In: Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research, pp. 201-204. Eds. H. Sinzinger. Plenum Press, New York.
10. Block R.I., Farinpour R., Braverman K. Acute effects of marijuana on cognition: Relationships to chronic effects and smoking techniques. Pharmacol. Biochem. Behav. 43:1992;907-917.
11. 1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270:1995;13973-13980.
12. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312:1995;637-641.
13. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., Calandra B., Le Fur G., Casellas P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237:1996;704-711.
14. Buchan B.J., Walsh J.M., Leaverton P.E. Evaluation of the accuracy of on-site multi-analyte drug testing devices in the determination of the prevalence of illicit drugs in drivers. J. Forensic. Sci. 43:1998;395-399.
15. Burkey T.H., Quock R.M., Consroe P., Ehlert F.J., Hosohata Y., Roeske W.R., Yamamura H.I. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur. J. Pharmacol. 336:1997;295-298.
16. Cabral G.A., Stinnett A.L., Bailey J. Chronic marijuana smoke alters alveolar macrophage morphology and protein expression. Pharmacol. Biochem. Behav. 40:1991;643-649.
17. Caenazzo L., Hoehe M.R., Hsieh W.T., Berrettini W.H., Bonner T.I., Gershon E.S. HindIII identifies a two allele DNA polymorphism of the human cannabinoid receptor gene (CNR). Nucleic Acids Res. 11:1991;4798.
18. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 16:1998;277-281.
19. Caput D., Ferrara P.J. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. Biol. Chem. 270:1995;3726-3731.
20. Carlini E.A., Cunha J.M. Hypnotic and antiepileptic effects of cannabidiol. J. Clin. Pharmacol. 21:1981;417S-427S.
21. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232.
22. Chait L.D., Perry J.L. Acute and residual effects of alcohol and marijuana smoking, alone and in combination, on mood and performance. Psychopharmacology. 115:1994;340-349.
23. Chan G.C.K., Hinds T.R., Impey S., Storm D.R. Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J. Neurosci. 18:1998;5322-5332.
24. Chen J.P., Paredes W., Li J., Smith D., Lowinson J., Gardner E.L. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology. 102:1990;156-162.
25. Chiang C.W.N., Barnett G. Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin. Pharmacol. Ther. 36:1984;234-238.
26. Childers S.R., Deadwyler S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 52:1996;189-827.
27. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann. N.Y. Acad. Sci. 654:1992;33-51.
28. Childers S.R., Sexton T., Roy M.B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711-715.
29. Clark S., Greene C., Karr G., Maccanneli K., Milstein S. Cardiovascular effects of marijuana in man. Can. J. Physiol. 52:1974;706-719.
30. Compton D.R., Johnson M.R., Meloin L.S., Martin B.R. Pharmacological evaluation of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260:1991;201-209.
31. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 285:1998;1150-1156.
32. Costa B., Paralaro D., Colleoni M. Chronic cannabinoid, CP-55 940, administration alters biotransformation in the rat. Eur. J. Pharmacol. 313:1996;17-24.
33. Court J.M. Cannabis and brain function. J. Paediatr. Child Health. 34:1998;1-5.
34. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
35. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomobility and hypothermia in-vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
36. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 21:1980;175-185.
37. 9-tetrahydrocannabinol is mediated by nuclear factor κB and CB1 cannabinoid receptor. DNA Cell. Biol. 16:1997;301-309.
38. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept. Channels. 1:1993;121-134.
39. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
40. Devane W.A., Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl Acad. Sci. USA. 91:1994;6698-6701.
41. Devane W.A., Spain J.W., Coscia C.J., Howlett A.C. An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J. Neurochem. 46:1992;1929-1935.
42. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
43. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
44. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
45. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
46. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonylglycerol is inactivated by neuronal- and basophil-like cells: connection with anandamide. Biochem. J. 331:1998;15-19.
47. Edery H., Grunfeld Y., Ben-Zvi Z., Mechoulam R. Structural requirements for cannabinoid activity. Ann. N.Y. Acad. Sci. 191:1971;40-53.
48. Feigenbaum J.J., Bergmann F., Richmond S.A., Mechoulam R., Nadler V., Kloog Y., Sokolovsky M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl Acad. Sci. USA. 186:1989;9584-9587.
49. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with an expressing cannabinoid receptor clones. Mol. Pharmacol. 42:1992;838-845.
50. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl Acad. Sci. USA. 90:1993;7656-7660.
51. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma L.A., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:1995;443-450.
52. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
53. Felder C.C., Joyce K.E., Briley E.M., Glass M., Mackie K.P., Fahey K.J., Cullinan G.J., Hunden D.C., Johnson D.W., Chaney M.O., Koppel G.A., Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 284:1998;291-297.
54. 9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci. Lett. 226:1997;159-162.
55. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 8:1997;649-652.
56. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272:1993;313-314.
57. Friedman, H., Shivers, S. C. and Klein, T. W. (1994) Drugs of abuse and the immune system. In: Immunotoxicology and Immunopharmacology, pp. 303-322. Eds. J. H. Dean, M. I. Luster, A. E. Munson and I. Kimber. Raven Press, New York.
58. Fukunaga K., Miyamoto E. Role of MAP kinase in neurons. Mol. Neurobiol. 16:1998;79-95.
59. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
60. Gaoni Y., Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
61. Garcia D.E., Brown S., Hille B., Mackie K. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J. Neurosci. 18:1998;2834-2841.
62. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279:1991;129-134.
63. Gessa G.L., Melis M., Muntoni A.L., Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol. 341:1998;39-44.
64. Gifford A.N., Samiian L., Gatley S.J., Ashby C.R. Examination of the effect of the cannabinoid receptor agonists, CP55,940, on electrically evoked transmitter release from rat brain slices. Eur. J. Pharmacol. 324:1997;187-192.
65. 2 receptors result in an augmentation of forskolin-stimulated cAMP in striatal neurons. Soc. Neurosci. Abstr. 615:1996;4.
66. Glass M., Faull R.L., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience. 56:1993;523-527.
67. Glass M., Faull R.L.M., Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study on the fetal, neonatal and adult human brain. Neuroscience. 77:1997;299-318.
68. 9-THC in the rat. Neuropharmacology. 17:1978;137-144.
69. Hampson R.E., Evans G.J., Mu J., Zhuang S.Y., King V.C., Childers S.R., Deadwyler S.A. Role of cyclic AMP dependent protein kinase in cannabinoid receptor modulation of potassium 'A-current' in cultured rat hippocampal neurons. Life Sci. 56:1995;2081-2088.
70. Heishman S.J., Huestis M.A., Henningfield J.E., Cone E.J. Acute and residual effects of marijuana: profils of plasma THC levels, physiological subjective, and performance measures. Pharmacol. Biochem. Behav. 37:1990;561-565.
71. Heishman S.J., Arasteh K., Stitzer M.L. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol. Biochem. Behav. 58:1997;93-101.
72. Henry D.J., Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 186:1995;91-94.
73. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA. 87:1990;1932-1936.
74. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in basal ganglia of the rat. Brain Res. 547:1991;267-274.
75. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in the rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
76. Herring A.C., Koh W.S., Kaminski N.E. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem. Pharmacol. 55:1998;1013-1023.
77. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology. 129:1997;99-111.
78. Heyser C.J., Hampson R.E., Deadwyler S.A. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264:1993;294-307.
79. Hillard C.J., Harris R.A., Bloom A.A. Effects of the cannabinoids on physiological properties of brain membranes and phospholipid vesicels: fluorescence studies. J. Pharmacol. Exp. Ther. 232:1985;579-588.
80. Hoehe M.R., Caenazzo L., Martinez M.M., Hsieh W.T., Modi W.S., Gershon E.S., Bonner T.I. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol. 3:1991;880-885.
81. Hoffman D., Brunneman D.K., Gori G.B., Wynder E.L. On the carcinogenicity of marijuana smoke. Recent Adv. Phytochem. 126:1975;63-81.
82. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
83. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma membranes. Mol. Pharmacol. 27:1985;429-436.
84. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the reponse in neuroblastoma cell membranes. Mol. Pharmacol. 26:1984;532-538.
85. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
86. Howlett A.C., Champion-Dorow T.M., McMahon L.L., Westlake T.M. The cannabinoid receptor: biochemical and cellular properties in neuroblastoma cells. Pharmacol. Biochem. Behav. 40:1991;565-569.
87. Ishac E.J., Jiang L., Lake K.D., Varga K., Abood M.E., Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118:1996;2023-2028.
88. Johnson, M. R. and Melvin, L. S. (1986) The discovery of nonclassical cannabinoid analgesics. In: Cannabinoids as Therapeutic Agents, pp. 121-145. Ed. R. Mechoulam. CRC Press, Boca Raton.
89. Johnson S., Domino E. Some cardiovascular effects of marihuna smoking in normal volunteers. Clin. Pharmacol. Ther. 12:1971;762-768.
90. Jones G., Pertwee R.G., Gill E.W., Paton W.D.M., Nilson I.M. Relative pharmacological potency in mice of optical isomers of delta-1-tetrahydrocannabinol. J. Med. Chem. 28:1974;783-787.
91. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42:1992;736-742.
92. Karler R., Turkanis S.A. The cannabinoids as potential antiepileptics. J. Clin. Pharmacol. 21:1981;437S-448S.
93. Klein T.W., Friedman H., Specter S. Marijuana, immunity and infection. J. Neuroimmunol. 83:1998;102-115.
94. 2+-dependent and -independent mechanisms. FEBS Lett. 429:1998;152-156.
95. Koob G.F. Neural mechanisms of drug reinforcement. Ann. N.Y. Acad. Sci. 28:1992;171-191.
96. Koob G.F. Drug addiction: the yin and yang of hedonic homeostasis. Neuron. 16:1996;893-896.
97. Kruszka K.K., Gross R.W. The ATP- and CoA-independent synthesis of arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J. Biol. Chem. 269:1994;14345-14348.
98. Kuster J.E., Stevenson J.I., Ward S.J., D'Ambra T.E., Haycock A. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 264:1993;1352-1363.
99. Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther. 281:1996;1030-1037.
100. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
101. Levenes C., Daniel H., Soubrié P., Crepel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J. Physiol. (Lond.). 510:1998;867-879.
102. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
103. 2-noradrenergic mechanism. Brain Res. 559:1991;309-314.
104. Lichtman A.H., Martin B.R. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology. 126:1996;125-131.
105. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
106. Lopez-Cepero M., Friedman M., Klein T., Friedman H. Tetrahydrocannabinol induced suppression of macrophages spreading and phagocytotic activity in vitro. J. Leukocyte Biol. 39:1986;679-686.
107. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 53:1997;239-258.
108. Lukas S.E., Mendelsen J.H., Benedikt R. Electroencephalographic correlates of marijuana-induced euphoria. Drug. Alcohol. Depend. 37:1995;131-140.
109. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl Acad. Sci. USA. 89:1992;3825-3829.
110. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
111. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1995;6552-6561.
112. MacLennan S.J., Reynen P.H., Kwan J., Bonhaus D.W. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol. 124:1998;619-622.
113. Mahmoudian N. The cannabinoid receptor: computer-aided molecular modeling and docking of ligand. J. Mol. Graph. Model. 15:1997;149-153.
114. Mailleux P., Vanderhaeghen J.J. Distribution of the neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-688.
115. Mailleux P., Vanderhaeghen J.J. Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hybridization study. Neurosci. Lett. 156:1993;51-53.
116. Mailleux P., Vanderhaeghen J.J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J. Neurochem. 61:1993;1705-1712.
117. Mailleux P., Vanderhaeghen J.J. Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur. J. Pharmacol. 266:1994;193-196.
118. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 308:1996;161-164.
119. Mansour A., Meador-Woodruff J.H., Zhou Q., Civelli O., Akil H., Watson S.J. A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience. 46:1992;959-971.
120. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Mol. Brain Res. 30:1998;126-132.
121. Martin B.R. Cellular effects of cannabinoids. Pharmacol. Rev. 38:1986;45-74.
122. Martin B.R., Balster R.L., Razdan R.K., Harris L.S., Dewey W.L. Behavioral comparisons of the stereoisomers of tetrahydrocannabinols. Life Sci. 29:1981;565-574.
123. Martin B.R., Compton D.R., Thomas B.F., Preskott W.R., Little P.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
124. Martin, W. J., Thomas, B. F. and Razdan, R. K. (1995) Structural requirements for cannabinoid receptor probes. In: Cannabinoid Receptors, pp. 35-85. Ed. R. G. Pertwee. Academic Press, London.
125. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
126. Martin W.J., Tsou K., Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. 242:1998;33-36.
127. Matsuda L.A. Molecular aspects of cannabinoid receptors. Crit. Rev. Neurobiol. 11:1997;143-166.
128. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
129. Matsuda L.A., Bonner T.I., Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327:1993;535-550.
130. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
131. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic canabinoid analogs. Mol. Pharmacol. 44:1993;1008-1015.
132. Merritt J., Crawford W., Alexander P., Anduze A., Gelbart S. Effects of marijuana on intraocular and blood pressure in glaucoma. Ophtamology. 87:1980;222-228.
133. Mintz I.M., Sabatini B.L., Regehr W.G. Calcium control of transmitter release at a cerebellar synapse. Neuron. 15:1995;675-688.
134. Moskowitz H. Marihuana and driving. Accid. Anal. Prev. 17:1985;323-345.
135. Moss D.E., McMaster S.B., Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol. Biochem. Behav. 15:1981;779-783.
136. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
137. Onaivi E.S., Chakrabarti A., Chaudhuri G. Cannabinoid receptor genes. Prog. Neurobiol. 48:1996;275-305.
138. Oviedo A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 616:1993;293-302.
139. Pacheco M.A., Childers S.R., Arnold R., Casiano F., Ward S.J. Aminoalkylindoles: actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257:1991;170-183.
140. Pacheco M.A., Ward S.J., Childers S.R. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res. 603:1993;102-110.
141. Pan X.H., Ikeda S.R., Lewis D.L. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol. Pharmacol. 49:1996;707-714.
142. Perez-Reyes M., Hicks R.E., Bumberry J., Jeffcoat A.R., Cook C.E. Interaction between marijuana and ethanol: effects on psychomotor performance. Alcoh. Clin. Exp. Res. 12:1988;201S-207S.
143. Perez-Reyes M., White W.R., McDonald S.A., Hicks R.E., Jeffcoat A.R., Cook C.E. The pharmacological effects of daily marijuana smoking in humans. Pharmacol. Biochem. Behav. 40:1991;691-694.
144. Pertwee, R. G. (1991) Tolerance to and dependence on psychotropic cannabinoids. In: The Biological Basis of Drug Tolerance and Dependence, pp. 231-263. Ed. J. A. Pratt. Academic Press, New York.
145. Pertwee R.G. The evidence for the existence of cannabinoid receptors. Gen. Pharmacol. 24:1993;811-824.
146. Pertwee R.G., Greentree S.G. Delta-9-tetrahydrocannabinol-induced in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology. 27:1988;485-491.
147. Pertwee R.G., Ross T.M. Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology. 30:1991;67-71.
148. Pertwee R.G., Wickens A.P. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology. 30:1991;237-244.
149. Pertwee R.G., Greentree S.G., Swift P.A. Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology. 27:1988;1265-1270.
150. Phillips T.J., Shen E.H. Neurochemical bases of locomotion and ethanol stimulant effects. Int. Rev. Neurobiol. 39:1996;243-282.
151. Pope H.G., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. J. Am. Med. Assoc. 275:1996;521-527.
152. 9-tetrahydrocannabinol and morphine in the spinal cord. J. Pharmacol. Exp. Ther. 279:1996;608-616.
153. Reichman M., Nen W., Hokin L.E. Delta-9-tetrahydrocannabinol inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea-pig cerebral cortex slices. Mol. Pharamcol. 40:1991;547-555.
154. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36:1994;577-584.
155. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.C., Le Fur G.L. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
156. Rinaldi-Carmona M., Calandra B., Shire D., Bouaboula M., Oustric D., Barth F., Casellas P., Ferrara P., Le Fur G.J. Characterization of two cloned human CB1 cannabinoid receptor isoforms. J. Pharmacol. Exp. Ther. 278:1996;871-878.
157. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
158. Robbe, H. W. (1994) Influence of Marijuana on Driving. University of Limburg Press, Maastrich.
159. Rodriguez de Fonseca F., Gorriti M., Fernandez R.J., Palomo T., Ramos J.A. Down regulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment. Pharmacol. Biochem. Behav. 47:1994;33-40.
160. Rodriguez de Fonseca F., Carrera M.R.A., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
161. Romero J., Garcia-Palomero E., Lin S.Y., Ramos J.A., Makriyannis A., Fernandez-Ruiz J.J. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sci. 58:1996;1249-1257.
162. 9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol. Brain Res. 46:1997;100-108.
163. 35S]guanylyl-5′O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience. 84:1998;1075-1083.
164. Romero J., de Miguel R., Ramos J.A., Fernández-Ruiz J.J. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci. 62:1998;351-363.
165. Rubino T., Patrini G., Parenti M., Massi P., Paroloro D. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Mol. Brain Res. 44:1997;191-197.
166. Rubino T., Patrini G., Massi P., Fuzio D., Vigano D., Giagnoni G., Parolaro D.J. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J. Pharmacol. Exp. Ther. 285:1998;813-819.
167. Sañudo-Peña M.C., Walker J.M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol. 77:1997;1635-1638.
168. Sañudo-Peña M.C., Patrick S.L., Patrick R.L., Walker J.M. Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopmainergic system. Neurosci. Lett. 206:1996;21-24.
169. Sañudo-Peña M.C., Patrick S.L., Khen S., Patrick R.L., Tsou K., Walker J.M. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett. 248:1998;171-174.
170. Scallet A.C. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol. Biochem. Behav. 40:1991;671-676.
171. Schaefer C., Brackett D., Gunn C., Dubowski K. Decreased platelet aggregation following marijuana smoking in man. J. Oklahoma State Med. Assoc. 72:1979;435-436.
172. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., Kaminski N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142:1997;278-287.
173. Schilstrom B., Svensson H.M., Svensson T.H., Nomikos G.G. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience. 85:1998;1005-1009.
174. 1 receptor-mediated inhibition of noradrnaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedebergs Arch. Pharmacol.
175. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375:1995;117-120.
176. Shen M., Thayer S.A. The cannabinoid agonist WIN55 212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783:1998;77-84.
177. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334.
178. Shimasue K., Urushidani T., Hagiwara M., Nagao T. Effects of anandamide and arachidonic acid on specific binding of (+)-PN200-110, diltiazem and (-)-desmethoxyverapamil to L-type Ca2+ channel. Eur. J. Pharmacol. 296:1996;347-350.
179. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
180. 35S]thio]-triphosphate binding. Proc. Natl Acad. Sci. USA. 92:1995;7242-7246.
181. Sinha D., Bonner T.I., Bhat N.R., Matsuda L.A. Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J. Neuroimmunol. 82:1998;13-21.
182. Slipetz D.M., O'Neill G.P., Favreau L., Dufresne C., Gallant M., Gareau Y., Guay D., Labelle M., Metters K.M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol. 48:1995;352-361.
183. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
184. 9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268:1994;1381-1387.
185. Smith F.L., Cichewicz D., Martin Z.L., Welch S.P. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 60:1998;559-566.
186. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 60:1998;183-191.
187. Solowij N., Michie T., Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol. Psychiatry. 37:1995;731-739.
188. Song C., Howlett A.C. Rat brain cannabinoid receptors are N-linked glycosylated proteins. Life Sci. 56:1995;1983-1989.
189. Souilhac J., Poncelet M., Rinaldi-Carmona M., Le Fur G., Soubrie P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol. Biochem. Behav. 51:1995;3-7.
190. 9-tetrahydrocannabinol. J. Leukocyte Biol. 50:1991;423-426.
191. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
192. Struve F., Straumanis J., Patrick G., Raz Y. Persistent topographic quantitative EEG sequelae of chronic marijuana use: a replication study and initial discriminant function analysis. Clin. Electroencephalogr. 25:1994;63-75.
193. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Ishima Y., Waku K. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240:1996;53-62.
194. Szabo B., Dörner L., Pfreundtner C., Nörenberg W., Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 85:1998;395-403.
195. Takahashi T., Momiyama A. Different types of calcium channels mediate central synaptic transmission. Nature. 366:1993;156-158.
196. 1 opioid receptor mechanism. Science. 276:1997;2048-2050.
197. Terranova J.P., Michaud J.C., Le Fur G., Soubrié P. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 352:1995;576-579.
198. Timpone J.G., Wright D.J., Li N., Egorin M.J., Enama M.E., Mayers J., Galetto G. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res. Hum. Retroviruses. 13:1997;305-315.
199. Tjeerdema R.S. The pyrolysis of cannabinoids. Rev. Environ. Contam. Toxicol. 99:1987;61-81.
200. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
201. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:1997;43-50.
202. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T.J. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. Biol. Chem. 270:1995;23823-23827.
203. Uliss D.B., Dalzell H.C., Handrick G.R., Howes J.F., Razdan R.K. Hashish. Importance of the phenolic hydroxyl group in tetrahydrocannabinols. J. Med. Chem. 18:1975;213-215.
204. Varga K., Lake K.D., Huangfu D., Guyenet P.G., Kunos G. Mechanism of the hypotensive action of anandamide in anestetized rats. Hypertension. 28:1996;682-686.
205. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature. 376:1995;590-594.
206. Vivian J.A., Kishioka S., Butelman E.R., Broadbear J., Lee K.O., Woods J.H. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J. Pharmacol. Exp. Ther. 286:1998;697-703.
207. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
208. Volicer L., Stelly M., Morris J., McLaughlin J., Volicer B.J. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry. 12:1997;913-919.
209. Voth E.A., Schwartz R.H. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann. Intern. Med. 126:1997;791-798.
210. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
211. Welch S.P. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.
212. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol. Depend. 45:1997;39-45.
213. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262:1992;10-18.
214. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
215. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiographic and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience. 63:1994;637-652.
216. 2+ channels in supporting hippocampal synaptic transmission. Science. 264:1994;107-111.
217. Willis W.D., Westlund K.N. Neuroanatomy of the pain system and of the pathways that modulate pain. J. Clin. Neurophysiol. 14:1997;2-31.
218. Wilson R.S., May E.L. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J. Med. Chem. 18:1975;700-703.
219. Wu T.C., Tashkin D.P., Djahed B., Rose J.E. Pulmonary hazards of smoking marijuana smoke. Recent Adv. Phytochem. 9:1983;63-81.
220. Yesavage J.A., Leirer V.O., Denari M., Hollister L.E. Carry-over effects of marijuana intoxication on aircraft pilot performance: a preliminary report. Am. J. Psychiat. 142:1985;1325-1329.
221. 9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of bcl-2 and caspase-1. J. Pharmacol. Exp. Ther. 286:1998;1103-1109.
222. Adams et al. (1998): AUTHOR - NOT CITED IN TEXT; PLEASE INSERT.
223. Cadas et al. (1997): AUTHOR - NOT CITED IN TEXT; PLEASE INSERT.
224. Devane et al. (1990): AUTHOR - NOT CITED IN TEXT; PLEASE INSERT.